GlobeNewswire

iCAD’s ProFound AI™ for 2D Mammography Receives CE Mark Approval

Share

Deep-learning, artificial intelligence technology assists radiologists in detecting breast cancer

NASHUA, N.H., July 11, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced its advanced artificial intelligence technology and workflow solution, ProFound AI™ for 2D Mammography, received CE Mark approval. The technology is the latest addition to iCAD’s deep-learning ProFound AI™ platform, joining ProFound AI™ for Digital Breast Tomosynthesis (DBT), which was CE Marked in March 2018, FDA-cleared in December 2018, and Health Canada licensed in July 2018. The technology was developed to support the detection of breast cancer through the identification of soft tissue densities and calcifications.

“Europe contains 9% of the world’s population but has more than 23% of the global cancer burden, with breast cancer being the most common cancer among European women,”1,2 stated Stacey Stevens, President of iCAD. “This CE Mark further validates our ProFound AI platform as a world-class artificial intelligence solution that offers benefits to both radiologists and screening-aged women in detecting breast cancer. iCAD is committed to improving patient care worldwide and we are pleased to offer this powerful technology to a growing number of hospitals, imaging centers and women across Europe.”

ProFound AI for 2D Mammography is a high-functioning, deep-learning algorithm that analyzes each mammography image and provides critical insight into each individual case, such as highlighting the most suspicious areas and assigning unique Certainty of Finding and Case Scores, which can assist radiologists in making clinical decisions and prioritizing caseloads. The ProFound AI platform is built upon the latest in deep-learning artificial intelligence and allows for continuously improved performance via ongoing software updates.

“ProFound AI for 2D Mammography has the potential to assist radiologists in their interpretation of 2D mammography images, as we have seen with ProFound AI for DBT,” according to Axel Gräwingholt, MD, Radiologie am Theater, in Paderborn, Germany. “As breast cancer rates continue to rise, it is imperative for radiologists to find cancers sooner, when they may be more easily treated, with fewer callbacks and false positives, which can be inconvenient and stressful for patients.”

For more information, visit www.icadmed.com.

References:

  1. GLOBOCAN 2018: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2018. https://www.uicc.org/news/new-global-cancer-data-globocan-2018. Accessed July 2019.
  2. United Nations, Population division. World Population Prospects, the 2019 revision. https://www.un.org/development/desa/publications/world-population-prospects-2019-highlights.html. Accessed July 2019.

About iCAD, Inc.

Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit www.icadmed.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.

Contacts:

Media Inquiries:
Jessica Burns, iCAD  
+1-201-423-4492
jburns@icadmed.com

Investor Relations:
Jeremy Feffer, LifeSci Advisors
+ 1-212-915-2568
jeremy@lifesciadvisors.com

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Signify to acquire Cooper Lighting Solutions to strengthen its position in the attractive North American lighting market15.10.2019 22:24:00 CESTPress release

Press release October 15, 2019 Signify to acquire Cooper Lighting Solutions to strengthen its position in the attractive North American lighting market Signify to acquire Cooper Lighting Solutions from Eaton for USD 1.4 billion in cash Clear strategic fit: Strengthening Signify’s market positions in North America, with increased innovation power and more competitive offerings; Improving the business mix with Professional revenues increasing from 42% to 53% of total sales1 Respective agent networks and front office functions will continue to operate independently Substantial value creation opportunity: cost synergy potential with savings of more than USD 60 million per year, to be largely achieved in the first three years Compelling financial metrics: mid-teens EPS accretion in year 1; transaction ROIC to exceed WACC after year 1 Transaction fully funded with debt; committed bridge financing in place Upon closing of the acquisition: Capital allocation priority is to deleverage. Strong f

Nexstim Plc: Invitation to the Extraordinary General Meeting of Shareholders15.10.2019 17:50:00 CESTPress release

Nexstim Plc: Invitation to the Extraordinary General Meeting of Shareholders Company announcement, inside information, Helsinki 15 October 2019 at 6.50 PM (EEST) Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") – the company developing and marketing a unique brain stimulation technology for personalized treatment of major depressive disorder (MDD), invites the shareholders to attend the Extraordinary General Meeting of Shareholders of the Company on 11 November 2019 commencing at 10.00 (EEST) at the auditorium of Hotel Haven, Unioninkatu 17 Helsinki, Finland. The reception of persons who have registered for the meeting will commence at 9.30. A. Matters on the agenda of the Extraordinary General Meeting of Shareholders At the Extraordinary General Meeting of Shareholders, the following matters will be considered: 1 OPENING OF THE MEETING 2 CALLING THE MEETING TO ORDER 3 ELECTION OF PERSONS TO SCRUTINIZE THE MINUTES AND TO SUPERVISE THE COUNTING OF VOTES 4 RECORDING THE LEGALI

Nexstim Abp: Kallelse till extra bolagsstämma15.10.2019 17:50:00 CESTPressemelding

Nexstim Abp: Kallelse till extra bolagsstämma Pressmeddelande, insiderinformation, Helsingfors 15 oktober 2019, kl. 18.50 (EEST) Nexstim Abp (NXTMH:HEX, NXTMS:STO) (”Nexstim” eller ”Bolaget”), ett företag som utvecklar och marknadsför en unik hjärnstimuleringsteknologi för personlig behandling av egentlig depression (eng. Major Depression Disorder), kallar härmed aktieägarna till extra bolagsstämma 11 november 2019, kl. 10.00 (EEST) i auditoriet på Hotel Haven, Unionsgatan 17 i Helsingfors, Finland. Mottagandet av personer som har registrerat sig för bolagsstämman inleds kl. 9.30. A. Ärenden på extrastämmans dagordning Vid extrastämman ska följande ärenden behandlas: 1 STÄMMANS ÖPPNANDE 2 STÄMMANS KONSTITUERING 3 VAL AV PROTOKOLLJUSTERARE OCH RÖSTRÄKNARE 4 FASTSTÄLLELSE AV ATT STÄMMAN BLIVIT BEHÖRIGEN SAMMANKALLAD 5 FASTSTÄLLANDE AV NÄRVAROLISTA OCH RÖSTLÄNGD 6 STYRELSEKOMMITTÉER OCH INRÄTTANDET AV VALBEREDNINGEN FÖR AKTIEÄGARNA Bolaget har haft två styrelsekommittéer: styrelsens revis

DNO ASA: Mandatory Notification of Trade15.10.2019 17:43:00 CESTPress release

Oslo, 15 October 2019 - DNO ASA, the Norwegian oil and gas operator, has today purchased 1,100,000 own shares at an average price of NOK 12.6653 per share. Following this transaction, DNO holds 75,500,000 own shares. -- For further information, please contact: Media: media@dno.no Investors: investor.relations@dno.no -- DNO ASA is a Norwegian oil and gas operator focused on the Middle East and the North Sea. Founded in 1971 and listed on the Oslo Stock Exchange, the Company holds stakes in onshore and offshore licenses at various stages of exploration, development and production in the Kurdistan region of Iraq, Norway, the United Kingdom, Netherlands, Ireland and Yemen. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Ress Life Investments A/S publishes Net Asset Value (NAV) per share.15.10.2019 17:20:00 CESTPress release

Ress Life Investments Holbergsgade 14, 2 tv DK-1057 Copenhagen K Denmark CVR nr. 33593163 www.resslifeinvestments.com To: Nasdaq Copenhagen Date: 15 October 2019 Corporate Announcement 34/2019 Ress Life Investments A/S publishes Net Asset Value (NAV) per share. Ress Life Investments A/S publishes the Net Asset Value (NAV) per share as of 30 September 2019. NAV per share in USD: 1918.35 NAV per share in EUR: 1761.73 The performance during September 2019 was 0.97% in USD. The performance during the month was positively affected by one policy paying out and mark-to-market adjustments. The year-to-date net performance as of 30 September 2019 is 5.76% in USD. Assets under management (AUM) as of 30 September 2019 was 155.1 million US dollars. Questions related to this announcement can be made to the company's AIF-manager, Resscapital AB. Contact person: Gustaf Hagerud gustaf.hagerud@resscapital.com Tel + 46 8 545 282 27 Note: The terms for subscription of shares, minimum subscription amount

GOGL – Repurchase of shares15.10.2019 16:44:00 CESTPress release

Golden Ocean Group Limited (“Golden Ocean” or the “Company”) announces that the Company has, on October 15, 2019 purchased 50,000 of the Company's own common stocks. The shares have been bought on the Oslo Stock Exchange at an average price of NOK 53.96 per share. After this transaction Golden Ocean holds a total of 1,250,000 own shares. The transaction is part of the share buyback program announced on December 20, 2018. Hamilton, Bermuda October 15, 2019 This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.